FOLFOX方案新辅助化疗在治疗进展期胃癌中的疗效观察

Clinical Observation of Neoadjuvant Chemotherapy with FOLFOX for Advanced Gastric Cancer

目的探讨FOLFOX方案新辅助化疗治疗进展期胃癌的临床疗效及不良反应。方法将73例进展期胃癌患者,随机分为观察组和对照组,对照组34例患者采取单纯手术治疗,观察组39例患者在手术治疗前给予FOLFOX方案新辅助化疗,比较2组患者的临床疗效,观察FOLFOX方案新辅助化疗的不良反应情况。结果观察组患者中ⅢB期的临床疗效最高,为68.8%,Ⅳ期最低,为53.8%。观察组治疗总有效率为61.5%,显著高于对照组的47.1%(P<0.05)。观察组患者在采用FOLFOX方案化疗后,恶心呕吐的发生率最高,为51.3%;其次为脱发和外周神经感觉障碍,均为48.7%。所有患者均未发生Ⅳ级不良反应。结论 FOLFOX新辅助化疗可进一步提高外科综合治疗效果,且不良作用小,患者耐受性高。

Objective To investigate the clinical efficacy and adverse reactions of neoadjuvant chemotherapy with FOLFOX for advanced gastric cancer. Methods 73 advanced gastric cancer patients were randomly divided into the observation group and the control group. 34 patients in the control group received simple operation, 39 patients in the observation group received FOLFOX with neoadjuvant chemotherapy before operation. Clinical efficacy of the 2 groups were compared, and the adverse reactions of the observation group were observed. Results The highest effective rate of the observation group was in stage ⅢB （68.8%） ,the lowest was in stage Ⅳ（53.8% ）. The total effective rate of observation group was 61.5% ,which was significantly higher than that of the control group （47.1% ,P 〈 O. 05 ）. The incidence of nausea and vomiting were the highest in the observa- tion group after FOLFOX chemotherapy （51. 3% ）; alopecia and sensory disturbance of peripheral nerves ranked second （48.7%）. No Ⅳ grade adverse reactions occurred in any patients. Conclusion Neoadjuvant chemotherapy with FOLFOX further：improves the surgical curative effect with tolerable adverse reactions.